NAS:PTCT (USA) Also Trade In: Germany
PTC Therapeutics Inc $ 63.36 0.31 (0.49%)
Warning! GuruFocus has detected 4 Severe warning signs with PTCT. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for PTCT (PTC Therapeutics Inc) from 2013 to Jan 25 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. PTC Therapeutics stock (PTCT) PE ratio as of Jan 25 2021 is 0. More Details
PTC Therapeutics PE Ratio (TTM) Historical Data
View and export this data going back to 2013. Start your Free Trial
PTC Therapeutics PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:ARWR NAS:HALO NAS:DCPH NAS:FGEN NYSE:BHVN NAS:ALLK NAS:BPMC NAS:BLUE NAS:FOLD NAS:AGIO OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 100 Corporate Court, South Plainfield, NJ, USA, 07080
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.